Comparative Quantitative Assessment of TUBB3 Expression Parameters in non-Small Cell Lung Cancer Tissue at Different Stages of the Disease
Open Access
- 11 November 2026
- journal article
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 71 (7-8) , 15-21
Abstract
Background . The importance of expanding the list of prognostic characteristics for stage 1 non-small cell lung cancer (NSCLC), which is characterized by the most favorable prognosis but poses a number of important tactical tasks for postoperative patient management, has been discussed in numerous studies. The aim of the study was to determine the pathogenetic and clinical significance of TUBB3 expression as a molecular marker of NSCLC aggressiveness at stage 1. Material and methods . A comparative analysis of TUBB3 expression in surgical samples of NSCLC (n = 64) at stages 1 and 3 was performed using flow cytometry-associated immunofluorescence. Primary monoclonal antibodies to TUBB3 (EP1569Y) and secondary antibodies conjugated with DyLight650 dye were used. Fluorescence was measured on a Navios flow cytometer. The number of stained cells was determined using the Kolmogorov–Smirnov test in FlowJo 10.0.8 software. Statistical analysis was performed using GraphPad Prism 6.0. Results. TUBB3 expression in stage 1 NSCLC tumors was shown to be higher than the median values for level (P = 0.000), intensity (P = 0.001), and integral index (P = 0.003) compared to stage 3 disease. For the integral index of the marker expression, the difference was nearly twofold. Conclusion . The detection of high expression of TUBB3 in NSCLC tissue at stage 1 of the disease should be considered among the prognostically unfavorable clinical and morphological characteristics of the tumor as an additional guideline for choosing optimal postoperative patient management.Keywords
This publication has 18 references indexed in Scilit:
- Recent advancements in colchicine derivatives: Exploring synthesis, activities, and nanoformulations for enhanced therapeutic efficacyDrug Discovery Today, 2025
- Identification of TUBB3 as an immunotherapy target in lung cancer by genome wide in vivo CRISPR screeningNeoplasia, 2024
- The significance of spread through air spaces in the prognostic assessment model of stage I lung adenocarcinoma and the exploration of its invasion mechanismJournal of Cancer Research and Clinical Oncology, 2023
- The epithelial-mesenchymal transition phenotype is associated with the frequency of tumor spread through air spaces (STAS) and a High risk of recurrence after resection of lung carcinomaLung Cancer, 2021
- Procedure-Specific Risk Prediction for Recurrence in Patients Undergoing Lobectomy or Sublobar Resection for Small (≤2 cm) Lung Adenocarcinoma: An International Cohort AnalysisJournal of Thoracic Oncology, 2019
- Lobectomy Is Associated with Better Outcomes than Sublobar Resection in Spread through Air Spaces (STAS)-Positive T1 Lung Adenocarcinoma: A Propensity Score–Matched AnalysisJournal of Thoracic Oncology, 2019
- Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum–paclitaxel chemotherapyCancer Chemotherapy and Pharmacology, 2014
- Longitudinal assessment of TUBB3 expression in non-small cell lung cancer patientsCancer Chemotherapy and Pharmacology, 2013
- RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLCLung Cancer, 2012
- Expression of ERCC1 and class III β-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiationCancer Chemotherapy and Pharmacology, 2009